Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Nogova L, Sequist LV, Garcia J, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. Journal Of Clinical Oncology 2016, 35: 157-165. PMID: 27870574, PMCID: PMC6865065, DOI: 10.1200/jco.2016.67.2048.Peer-Reviewed Original ResearchConceptsFibroblast growth factor receptorGrowth factor receptorUrothelial cancerSafety profileAntitumor activitySolid tumorsGenetic alterationsKinase inhibitorsDose-expansion studyFGFR genetic alterationsMethods Adult patientsMTD/RP2DCommon adverse eventsManageable safety profilePhase II doseSimilar safety profileAdvanced solid tumorsContinuous scheduleDose-limiting toxicityFactor receptorCell lung cancerGrowth factor receptor 1Tyrosine kinase inhibitorsFibroblast growth factor receptor 1Factor receptor 1